Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 19/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7644039 | 0.76 | GAA (0.61) | TNIKKDM4EALDH1A1LMNAGAA | |
| SCHEMBL9841681 | 0.76 | TNIK (0.34) | TNIKKDM4EALDH1A1LMNAGAA | |
| SCHEMBL30764866 | 0.75 | MAPT (0.49) | ALDH1A1LMNAMAPT | |
| SCHEMBL21247709 | 0.73 | TNIK (1.00) | TNIK | |
| SCHEMBL9820118 | 0.72 | TNIK (0.50) | TNIKALDH1A1LMNAGAAMAPT | |
| SCHEMBL30640050 | 0.71 | POLB (0.47) | TNIKLMNAMAPT | |
| SCHEMBL21248467 | 0.71 | TNIK (1.00) | TNIK | |
| SCHEMBL21262446 | 0.71 | TNIK (0.80) | TNIK | |
| SCHEMBL29966051 | 0.71 | TNIK (0.80) | TNIK | |
| SCHEMBL29965844 | 0.71 | TNIK (1.00) | TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | TNIK 3/4885KDM4E 1710/4885ALDH1A1 4519/4885 |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | TNIK 3/4885KDM4E 1710/4885ALDH1A1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.